A. Menarini Asia-Pacific Holdings Pte Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:A. Menarini Asia-Pacific Holdings Pte Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013138
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:シンガポール
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
A. Menarini Asia-Pacific Holdings Pte Ltd (A. Menarini Asia-Pacific), formerly Invida Group Pte Ltd, a subsidiary of A. Menarini Industrie Farmaceutiche Riunite Srl is a biopharmaceutical company that develops consumer health care products. The company operates through its divisions including R and D, biotech and diagnostics. Its R and D division access to global network of research and development infrastructure. A. Menarini Asia-Pacific’s biotech division develops and manufactures bio-pharmaceuticals, using mammalian cells and microbial production systems. The company’s diagnostics division provides technological solutions for healthcare professionals. It serves in the area of diabetes, autoimmunity, cell pathology, hemoglobin analysis, urine analysis, and others. A. Menarini Asia-Pacific is headquartered in Singapore.

A. Menarini Asia-Pacific Holdings Pte Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
A. Menarini Asia-Pacific Holdings Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
A. Menarini Asia-Pacific Holdings Pte Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
A. Menarini Asia-Pacific Holdings Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
A. Menarini Asia-Pacific Holdings Pte Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
A. Menarini Asia-Pacific Holdings Pte Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
A. Menarini Asia-Pacific Holdings Pte Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Invida Acquires Dermatology And Primary Care Product Portfolios From Shalaks Pharma For US$20 Million 10
Partnerships 12
Menarini Asia-Pacific Enters into Agreement with Merck 12
Moberg Pharma Extends Distribution Agreement With Menarini 13
Moberg Extends Distribution Agreement With Menarini For Kerasal Nail 14
Menarini Enters Into Commercialization Agreement With Gilead Sciences For Ranexa 15
Sinclair Pharma Extends Co-Marketing Agreement With Invida 16
Invida Group Enters Into Agreement With F. Hoffmann-La Roche 17
Licensing Agreements 19
Menarini Enters into Licensing Agreement with Mitsubishi Tanabe Pharma for Spedra 19
Almirall Enters Into Licensing Agreement With Invida For Aclidinium 20
Faes Farma And Invida Enter Into Licensing Agreement For Bilastine 21
Orexo Enters Into Licensing Agreement With Invida Group For Abstral 22
Acquisition 23
Menarini Group Acquires Invida 23
A. Menarini Asia-Pacific Holdings Pte Ltd – Key Competitors 25
A. Menarini Asia-Pacific Holdings Pte Ltd – Key Employees 26
A. Menarini Asia-Pacific Holdings Pte Ltd – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 29
Other Significant Developments 29
Jun 09, 2016: Menarini Group and MSD Extends Global Partnership to the Asia-Pacific Region 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
A. Menarini Asia-Pacific Holdings Pte Ltd, Pharmaceuticals & Healthcare, Key Facts 2
A. Menarini Asia-Pacific Holdings Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
A. Menarini Asia-Pacific Holdings Pte Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
A. Menarini Asia-Pacific Holdings Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
A. Menarini Asia-Pacific Holdings Pte Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
A. Menarini Asia-Pacific Holdings Pte Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Invida Acquires Dermatology And Primary Care Product Portfolios From Shalaks Pharma For US$20 Million 10
Menarini Asia-Pacific Enters into Agreement with Merck 12
Moberg Pharma Extends Distribution Agreement With Menarini 13
Moberg Extends Distribution Agreement With Menarini For Kerasal Nail 14
Menarini Enters Into Commercialization Agreement With Gilead Sciences For Ranexa 15
Sinclair Pharma Extends Co-Marketing Agreement With Invida 16
Invida Group Enters Into Agreement With F. Hoffmann-La Roche 17
Menarini Enters into Licensing Agreement with Mitsubishi Tanabe Pharma for Spedra 19
Almirall Enters Into Licensing Agreement With Invida For Aclidinium 20
Faes Farma And Invida Enter Into Licensing Agreement For Bilastine 21
Orexo Enters Into Licensing Agreement With Invida Group For Abstral 22
Menarini Group Acquires Invida 23
A. Menarini Asia-Pacific Holdings Pte Ltd, Key Competitors 25
A. Menarini Asia-Pacific Holdings Pte Ltd, Key Employees 26
A. Menarini Asia-Pacific Holdings Pte Ltd, Subsidiaries 27

★海外企業調査レポート[A. Menarini Asia-Pacific Holdings Pte Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Gazprom Neft (SIBN):石油・ガス:M&Aディール及び事業提携情報
    Summary Gazprom Neft, a subsidiary of Gazprom, is an integrated oil and gas company. It explores for, develops, and produces crude oil and natural gas. The company operates in Khanty-Mansi and Yamalo-Nenets Autonomous Districts, and Tomsk, Omsk and Orenburg regions in Russia; and also has production …
  • Vitec Group plc (VTC):企業の財務・戦略的SWOT分析
    Vitec Group plc (VTC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Envipco Holding NV (ENVI):企業の財務・戦略的SWOT分析
    Envipco Holding NV (ENVI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Sicon Ltd:企業の戦略・SWOT・財務情報
    Sicon Ltd - Strategy, SWOT and Corporate Finance Report Summary Sicon Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Vindhya Telelinks Ltd:企業の戦略・SWOT・財務情報
    Vindhya Telelinks Ltd - Strategy, SWOT and Corporate Finance Report Summary Vindhya Telelinks Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Tragara Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Tragara Pharmaceuticals Inc (Tragara Pharmaceuticals) is a pharmaceutical company focused on the clinical and commercial development of its proprietary medicines for the treatment of various cancers. Its lead product candidate TG02, an oral multi-kinase inhibitor facilitates anti-tumor activ …
  • ConAgra Foods Inc:戦略・SWOT・企業財務分析
    ConAgra Foods Inc - Strategy, SWOT and Corporate Finance Report Summary ConAgra Foods Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Wolters Kluwer N.V. (WKL):企業の財務・戦略的SWOT分析
    Wolters Kluwer N.V. (WKL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Nuri Telecom Co., Ltd. (040160):企業の財務・戦略的SWOT分析
    Nuri Telecom Co., Ltd. (040160) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Sumatec Resources Bhd (SUMATEC):石油・ガス:M&Aディール及び事業提携情報
    Summary Sumatec Resources Bhd (Sumatec) is an oilfield service provider that offers of construction and drilling services to the oil and gas industry. The company’s services include engineering and construction for oil and gas facilities, oil and gas assets development, supply and management of onsh …
  • Allianz Seguros SA:企業の戦略・SWOT・財務分析
    Allianz Seguros SA - Strategy, SWOT and Corporate Finance Report Summary Allianz Seguros SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Techtronic Industries Co Ltd (669)
    Techtronic Industries Co Ltd (669) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Alexion Pharmaceuticals Inc (ALXN)-製薬・医療分野:企業M&A・提携分析
    Summary Alexion Pharmaceuticals Inc (Alexion) focuses on developing and delivering life-changing drug therapies for patients with serious and ultra-rare disorders. The company develops biologic therapeutic products for the treatment of severe disease states, including genetic diseases, hematologic d …
  • 3M Company:戦略・SWOT・企業財務分析
    3M Company - Strategy, SWOT and Corporate Finance Report Summary 3M Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • AnaMar AB:医療機器:M&Aディール及び事業提携情報
    Summary AnaMar AB (AnaMar), a subsidiary of Koncentra Holding AB, is a drug discovery company that discovers, develops and commercializes therapeutic strategies to treat debilitating inflammation, fibrosis and pain. The company develops drug candidates from several chemical classes on the receptors …
  • Mammoth Energy Services Inc (TUSK):石油・ガス:M&Aディール及び事業提携情報
    Summary Mammoth Energy Services Inc (Mammoth) is a provider of an integrated oilfield services. Its suite of services include pressure pumping, infrastructure services, natural sand proppant, contract land and directional drilling, and remote accommodation. Mammoth serves companies involved in the e …
  • Kohinoor Energy Limited:発電所・企業SWOT分析
    Kohinoor Energy Limited - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emplo …
  • Exor N.V:企業の戦略・SWOT・財務分析
    Exor N.V - Strategy, SWOT and Corporate Finance Report Summary Exor N.V - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Atkins Limited:企業のM&A・事業提携・投資動向
    Atkins Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Atkins Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Antitope Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Antitope Ltd (Antitope), a subsidiary of Abzena Plc is a life science company that research and develops technologies for various therapeutic areas. The company’s iTope technology is used to identify peptides; and T Cell Epitope Database is used for screening amino acid sequences from antibo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆